CITED2 and breast cancer: Preliminary analyses in a subset of 120 patients for whom the molecular breast cancer subtype was known suggest that NCOR2 and CITED2 mRNA levels are particularly prognostic in patients with luminal A tumours, but not luminal B tumours (data not shown).